Product Description
Mechanisms of Action: Capsid Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vaxart
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Andrei Floroiu
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Common Cold|Emphysema|Enterovirus Infections|Healthy Volunteers|Respiratory Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06149494 |
ALT VPV-202 | P2 |
Completed |
Respiratory Tract Infections|Common Cold|Enterovirus Infections|Emphysema|Chronic Obstructive Pulmonary Disease |
2025-03-30 |
12% |
2025-10-01 |
Primary Endpoints|Treatments|Trial Status |
NCT05962645 |
ALT VPV-101 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2023-12-12 |
51% |
2024-07-31 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06834295 |
ALT VPV-102 | P2 |
Completed |
Healthy Volunteers |
2025-03-23 |
12% |
2025-05-29 |